When will repatha be generic?

Patent Expiration and Repatha Availability

Repatha, an injectable medication used to treat high cholesterol and cardiovascular disease, is a biologic product with a complex patent landscape.

Why is Repatha's patent expiration important to patients?

Patent expiration marks the end of pharmaceutical companies' exclusive rights to manufacture and sell these medications. This can lead to the emergence of generic or biosimilar versions. For patients, generic medications often offer lower prices and increased access.

When does Repatha's exclusivity expire?

The patents for Repatha (evolocumab) are set to expire at various times. According to the patent information on DrugPatentWatch.com, several of Repatha's key patents are set to expire between 2026 and 2037 [1]. However, the actual expiration date may differ based on various factors, including patent disputes or new patents issued.

What impact will generic Repatha have on prices?

Generic or biosimilar versions of Repatha could lead to lower prices, making the medication more accessible to patients. The price competition would likely decrease the cost of the medication, but the exact impact on prices is uncertain.

Are biosimilars already available for Repatha?

No, biosimilar versions of Repatha have not yet entered the market. However, several biosimilar applications are underway, pending regulatory approval.

What's the outlook for Repatha generics?

The availability of Repatha generics will depend on various factors, including patent expiration dates, regulatory approvals, and market competition. As the patent landscape evolves, we can expect to see more information on generic Repatha options.

Sources:
[
1] DrugPatentWatch.com, accessed on December 2023.